protein
product
fraction
human
plasma
essenti
class
therapeut
use
often
avail
option
prevent
manag
treatment
lifethreaten
condit
result
trauma
congenit
defici
immunolog
disord
infect
modern
plasma
product
product
technolog
remain
larg
base
ethanol
fraction
process
much
evolv
last
year
improv
product
puriti
enhanc
recoveri
immunoglobulin
g
isol
new
plasma
protein
inhibitor
von
willebrand
factor
protein
c
human
origin
start
materi
pool
donat
requir
industri
process
major
risk
associ
plasma
product
transmiss
bloodborn
infecti
agent
complet
set
measuresand
particularli
use
dedic
viral
inactiv
remov
treatmentsha
implement
throughout
product
chain
fraction
plasma
product
last
year
ensur
optim
safeti
particular
exclus
hiv
hepat
b
viru
hepat
c
viru
review
summar
practic
modern
plasma
fraction
industri
collect
raw
plasma
materi
industri
manufactur
fraction
product
describ
qualiti
requir
plasma
fraction
variou
treatment
appli
inactiv
remov
bloodborn
infecti
agent
provid
exampl
method
use
purif
variou
class
plasma
protein
therapi
also
highlight
aspect
good
manufactur
practic
regulatori
environ
govern
whole
chain
product
regul
profession
environ
fraction
plasma
product
manufactur
modern
process
certainli
among
lowestrisk
therapeut
biolog
product
use
today
elsevi
inc
right
reserv
c
ollect
human
plasma
may
use
therapeut
product
known
bclinic
plasmaq
bfresh
frozen
plasmaq
sourc
materi
product
pharmaceut
fraction
product
also
call
bplasma
productsq
bplasma
derivativesq
complex
biolog
materi
contain
hundr
protein
cover
myriad
physiolog
function
mani
compon
still
undiscov
role
abund
protein
albumin
immunoglobulin
ig
g
present
gl
respect
repres
plasma
protein
less
abund
protein
includ
proteas
inhibitor
like
aat
gl
antithrombin
mgl
coagul
factor
factor
viii
fviii
ngl
exhibit
potent
physiolog
activ
current
differ
plasma
protein
therapeut
use
treat
lifethreaten
diseas
injuri
associ
bleed
thrombot
disord
immunolog
diseas
infecti
condit
well
tissu
degener
diseas
thu
address
clinic
need
countless
patient
updat
list
major
therapeut
applic
plasma
protein
product
found
elsewher
industri
process
use
isol
therapeut
plasma
protein
known
bfractionationq
million
liter
human
plasma
fraction
year
world
batch
sever
thousand
liter
factori
modern
plasma
fraction
combin
manufactur
step
isol
sequenti
integr
manner
crude
fraction
purifi
individu
therapeut
product
valid
dedic
step
inactiv
andor
remov
infecti
agent
potenti
present
start
plasma
pool
sophist
industri
process
perform
highli
hygien
condit
licens
facil
plasma
fraction
plant
oper
complianc
good
manufactur
practic
follow
qualiti
assur
principl
year
plasma
fraction
evolv
medic
servic
activ
mostli
orient
toward
need
local
commun
global
manufactur
industri
conform
high
regulatori
standard
strict
requir
start
collect
plasma
fraction
includ
product
manufactur
distribut
step
articl
review
current
practic
encompass
collect
plasma
fraction
core
industri
plasma
fraction
process
purif
pathogen
reduct
technolog
individu
plasma
product
practic
use
collect
plasma
fraction
direct
influenc
safeti
profil
protein
product
sinc
individu
donat
contribut
larg
plasma
pool
use
manufactur
therapeut
prepar
intend
hundr
even
thousand
patient
therefor
logic
product
plasma
regard
integr
part
manufactur
modern
fraction
product
collect
requir
plasma
fraction
may
differ
relev
fresh
frozen
plasma
regul
environ
plasma
fraction
collect
licensedregist
blood
establish
blood
center
apheresi
collect
center
inspect
relev
nation
regulatori
author
nra
compel
safeti
concern
plasma
fraction
conduct
audit
verifi
contractu
plasma
collect
qualiti
safeti
measur
agre
upon
plasma
supplier
met
area
specif
relev
includ
procedur
donor
screen
donat
test
b
label
document
traceabl
requir
c
handl
blood
plasma
inform
part
market
licens
plasma
product
europ
assembl
document
call
bplasma
master
fileq
variou
requir
collect
plasma
fraction
describ
variou
guid
eg
pharmaceut
inspect
convent
pharmaceut
inspect
cooper
scheme
jointli
refer
pic
us
food
drug
administr
fda
recent
world
health
organ
recommend
summar
candid
donor
provid
educ
materi
undergo
medic
interview
establish
absenc
risk
sign
infect
prove
complianc
donat
plasma
fraction
tabl
potenti
donor
present
health
hazard
ask
exclud
medic
inform
donor
acquir
archiv
continu
epidemiolog
surveil
donor
popul
requir
jurisdict
help
establish
background
level
preval
incid
trend
known
infecti
marker
eg
hiv
antibodi
hepat
c
viru
hcv
antibodi
hepat
b
surfac
antigen
hbsag
popul
also
interest
earli
detect
emerg
diseas
allow
earli
implement
counter
measur
stringent
donor
screen
process
requir
addit
test
procedur
donor
elig
donat
plasma
fraction
individu
meet
donat
criteria
age
donat
frequenc
present
risk
factor
bloodborn
infecti
agent
compli
requir
defin
plasma
fraction
nra
countri
plasma
collect
use
product
situat
elig
whole
blood
donor
apheresi
donor
overlap
apart
donat
frequenc
higher
plasmapheresi
donor
elig
criteria
take
account
scientif
inform
risk
transmiss
infecti
agent
pool
plasma
product
may
differ
blood
compon
special
criteria
may
exist
collect
hyperimmun
plasma
use
make
hyperimmun
igg
prepar
procedur
donor
immun
minim
antibodi
titer
current
plasma
fraction
world
obtain
centrifug
whole
blood
brecoveredq
plasma
obtain
apheresi
bloodplasma
collect
process
storag
may
affect
plasma
qualiti
well
impact
recoveri
labil
protein
fviii
particular
risk
activ
coagul
complement
fibrinolyt
system
may
lead
gener
plasma
proteas
avoid
better
preserv
integr
recov
plasma
limit
risk
activ
coagul
cascad
cellular
compon
good
mix
blood
anticoagul
solut
sodium
citrat
base
solut
ensur
initi
till
end
collect
process
b
durat
collect
exceed
minut
c
temperatur
variat
blood
avoid
hour
donat
whole
blood
subject
centrifug
separ
cellular
element
specif
red
cell
plasma
mean
plasma
volum
obtain
one
whole
blood
donat
ml
vari
depend
upon
volum
collect
whole
blood
often
ml
donor
hematocrit
apheresi
plasma
also
call
bsourc
plasmaq
collect
donor
process
blood
remov
donor
anticoagul
gener
sodium
citrat
solut
immedi
separ
physic
mean
centrifug
filtrat
combin
compon
minimum
red
cell
return
donor
plasma
retain
collect
contain
bag
plastic
bottl
durat
typic
plasmapheresi
procedur
depend
number
cycl
henc
volum
plasma
collect
last
gener
minut
apheresi
plasma
volum
may
rang
ml
depend
upon
countri
regul
collect
protocol
apheresi
plasma
also
prepar
byproduct
plateletpheresi
bconcurr
plasmaq
procedur
use
primarili
collect
platelet
recov
apheresi
plasma
suitabl
manufactur
whole
rang
fraction
plasma
product
mean
content
coagul
factor
particularli
fviii
lower
recov
apheresi
plasma
longer
process
time
freez
whole
blood
must
process
separ
cellular
compon
plasma
b
higher
ratio
anticoagul
possibl
c
higher
level
cellular
contamin
may
releas
proteolyt
enzym
affect
stabil
coagul
factor
apheresi
plasma
contain
less
igg
collect
frequent
donor
protein
content
qualiti
fraction
protein
appar
affect
apheresi
system
use
although
residu
cell
content
differ
base
upon
type
configur
cell
separ
devic
plasma
membran
apheresi
procedur
recov
plasma
prepar
whole
blood
leukoreduc
posit
charg
filter
may
fraction
ymandatori
europ
hcv
zmay
contribut
viral
clearanc
necessarili
result
robust
consist
remov
small
virus
robust
remov
achiev
narrow
pore
size
membran
nm
texpect
contribut
base
experiment
studi
use
spike
tse
agent
absenc
inform
biolog
natur
tsehuman
plasma
associ
agent
contain
activ
complement
compon
anaphylatoxin
impact
qualiti
yield
fraction
product
unknown
variou
infecti
agent
identifi
potenti
contamin
human
blood
bacteria
parasit
intracellular
virus
transmit
plasma
product
destroy
freezethaw
step
remov
filtrat
step
use
process
fraction
product
pathogen
plasmaborn
virus
includ
hiv
hcv
hepat
b
viru
hbv
west
nile
viru
wnv
hepat
viru
hav
parvoviru
variou
complementari
safeti
net
place
product
chain
fraction
product
donor
select
industri
product
extract
optim
safeti
agent
summar
tabl
import
viral
test
safeti
plasma
product
review
extent
viral
test
plasma
fraction
take
account
abil
valid
fraction
process
elimin
viral
risk
test
perform
blood
establish
plasma
fraction
tabl
individu
plasma
donat
must
neg
antihiv
antihcv
hbsag
genom
assay
plasma
minipool
nonenvelop
hav
may
perform
relev
test
absenc
hiv
wnv
nucleic
acid
test
nat
may
justifi
safeti
nonvir
inactiv
blood
compon
arguabl
plasma
fraction
subject
robust
viral
reduct
step
envelop
virus
industri
manufactur
pool
usual
cryopoor
plasma
first
homogen
pool
plasma
fraction
also
test
confirm
absenc
serolog
andor
genom
viral
marker
hiv
hbv
hcv
hav
spite
rigor
donor
screen
donat
test
infecti
virus
may
still
present
plasma
fraction
pool
therefor
viral
inactivationremov
step
deliber
introduc
plasma
product
manufactureand
describ
belowplay
critic
role
ensur
safeti
altogeth
overlap
test
ensur
viral
load
manufactur
minim
significantli
viral
reduct
capac
manufactur
process
use
preserv
fviii
bloodplasma
collect
prepar
import
fraction
prepar
coagul
factor
concentr
apheresi
plasma
gener
frozen
quickli
ensur
optim
fviii
preserv
contrast
whole
blood
centrifug
separ
variou
compon
blood
cool
collect
plasma
separ
frozen
within
hour
preserv
fviii
cool
rapidli
constant
use
devic
like
butanediol
plate
coagul
factor
stabl
hour
plasma
frozen
within
hour
suitabl
igg
albumin
product
separ
cellular
element
plasma
fraction
frozen
rapidli
depend
upon
local
regul
plasma
use
manufactur
albumin
igg
may
frozen
within
hour
collect
us
code
feder
regul
apheresi
plasma
store
colder
immedi
collect
rapid
plasma
freez
ensur
rapid
ice
front
veloc
core
temperatur
preserv
fviii
appear
import
actual
freez
temperatur
plasma
fraction
store
less
colder
typic
sever
month
storag
temperatur
constant
possibl
includ
transport
fraction
facil
crosscontin
intercontin
shipment
plasma
fraction
frequent
product
step
take
place
fraction
plant
summar
figur
typic
plasma
protein
downstream
method
present
tabl
physic
complianc
ship
requir
verifi
deliveri
plasma
frozen
plasma
expel
plastic
contain
pool
cryoprecipit
manufactur
step
describ
intermedi
fraction
gener
product
may
store
subsequ
pool
process
purifi
sterilefilt
product
asept
dispens
final
contain
glass
vial
bottl
albumin
bottl
undergo
termin
pasteur
mani
product
albumin
igg
prepar
freezedri
typic
durat
day
depend
upon
physicochem
characterist
fill
volum
batch
quarantin
qualiti
control
check
product
file
take
place
batch
meet
specif
label
packag
subsequ
box
ship
distribut
countri
product
batch
may
releas
regulatori
author
product
cycl
fraction
product
take
week
sever
month
current
core
fraction
technolog
larg
reli
backbon
process
encompass
cryoprecipit
cold
ethanol
precipit
step
develop
cohn
et
al
unit
state
modifi
kistler
nitschman
europ
process
involv
success
process
step
defin
ethanol
concentr
associ
shift
ph
temperatur
osmol
result
select
precipit
protein
notabl
igg
albumin
precipit
separ
centrifug
filtrat
last
year
complex
fraction
process
increas
introduct
chromatographi
isol
new
protein
exist
fraction
cryoprecipit
cryopoor
plasma
cohn
fraction
b
integr
chromatographi
ethanol
fraction
process
increas
igg
recoveri
c
implement
dedic
viral
inactiv
remov
step
chromatographi
introduc
howev
applic
develop
mostli
midlat
anionexchang
chromatographi
affin
chromatographi
frequent
use
captur
protein
physiolog
ph
ionic
strength
therefor
best
preserv
function
activ
immobil
heparin
monoclon
antibodi
common
affin
chromatographi
ligand
chromatographi
use
specif
goal
improv
product
puriti
b
extract
trace
labil
protein
c
optim
protein
recoveri
remov
viral
inactiv
agent
figur
illustr
typic
industri
fraction
scheme
standard
plasma
plasma
pack
typic
batch
l
open
hygien
condit
plasma
expel
contain
thaw
cryoprecipit
isol
use
refriger
continu
centrifug
recov
centrifug
bowl
frozen
colder
storag
pool
process
cryopoor
plasma
immedi
process
primari
chromatograph
captur
labil
coagul
factor
factor
ix
fix
complex
compon
proteas
inhibitor
esteras
inhibitor
prepurifi
intermedi
may
store
frozen
process
coagul
factor
anticoagulantdeplet
plasma
undergo
sequenti
ethanol
precipit
step
lead
success
precipit
fibrinogen
igg
albumin
fraction
intermedi
extract
therapeut
protein
aat
fraction
igm
fraction
iii
depth
filtrat
prefer
centrifug
separ
precipit
improv
protein
recoveri
fraction
hyperimmun
plasma
eg
antirhesu
usual
perform
small
plasma
batch
size
increa
ingli
use
full
chromatograph
process
optim
recoveri
igg
document
transmiss
hiv
hbv
hcv
product
subject
dedic
viral
inactiv
treatment
record
sinc
end
viral
reduct
treatment
includ
inactiv
step
virus
bkilledq
remov
step
virus
protein
partit
distinct
fraction
use
one
prefer
two
distinct
dedic
viral
reduct
treatment
current
bgold
standardq
plasma
product
first
treatment
perform
primarili
inactiv
pathogen
virus
hiv
hbv
hcv
wherea
second
reduct
step
target
nonenvelop
virus
also
contribut
ad
safeti
agent
viral
reduct
treatment
integr
protein
fraction
process
binprocessq
treatment
current
base
heat
inactiv
procedur
appli
product
fill
final
contain
termin
treatment
fraction
requir
regulatori
author
conduct
downscal
experiment
valid
studi
use
relev
model
virus
establish
efficaci
robust
viral
reduct
procedur
robust
viral
reduct
procedur
place
exemplifi
absenc
transmiss
wnv
emerg
viru
similarli
lipidenvelop
sever
acut
respiratori
syndrom
coronaviru
shown
inactiv
core
viral
inactiv
treatment
plasma
product
also
like
proven
valid
experi
yet
avian
flu
simian
foami
virus
also
lipid
envelop
would
inactiv
current
process
place
present
plasma
detail
viral
valid
procedur
found
elsewher
major
characterist
current
viral
reduct
treatment
summar
tabl
discuss
briefli
inprocess
viral
inactiv
treatment
solventdeterg
sd
treatment
develop
mid
remain
frequent
core
viral
inactiv
procedur
plasma
product
protein
solut
incub
hour
presenc
trinbutyl
phosphat
tnbp
triton
typic
lipid
envelop
virus
inactiv
matter
minut
function
activ
even
labil
plasma
proteinswith
possibl
except
serin
proleas
inhibitorsi
well
preserv
nonenvelop
virus
less
pathogen
individu
inactiv
sd
agent
remov
level
part
per
million
usual
chromatograph
adsorpt
specif
precipit
protein
select
adsorpt
hydrophob
chromatograph
support
pasteur
anoth
common
viral
inactiv
procedur
heat
treatment
protein
solut
hour
treatment
denatur
viral
protein
inhibit
viru
replic
pasteur
inactiv
envelop
nonenvelop
virus
stabil
need
limit
loss
protein
function
may
decreas
rate
extent
viral
inactiv
stabil
may
remov
ultrafiltr
protein
precipit
chromatographi
vapor
heat
also
use
one
compani
extent
viru
inactiv
influenc
temperatur
durat
pressur
treatment
risk
neoantigen
format
enhanc
protein
immunogen
consid
use
heatbas
inactiv
process
low
ph
incub
usual
ph
hour
introduc
earli
allow
intraven
infus
igg
form
treatment
subsequ
found
inactiv
lipidenvelop
virus
capryl
octano
acid
precipitationincub
ph
recent
introduc
treatment
human
igg
inactiv
lipidenvelop
virus
termin
viral
inactiv
treatment
modern
plasma
fraction
heat
treatment
lyophil
product
dri
heat
use
due
limit
mostli
secondari
viral
inactiv
step
rather
core
inactiv
treatment
treatment
appli
coagul
factor
concentr
perform
hour
minut
gener
presenc
protein
stabil
provid
ad
safeti
havand
heatsensit
virus
may
suffici
exclud
transmiss
termin
liquid
pasteur
hour
bgold
standardq
treatment
albumin
prepar
fatti
acid
capryl
tryptophan
protect
albumin
heat
denatur
ad
dose
compat
therapeut
use
therefor
remov
product
infus
viral
remov
treatment
nanofiltr
specif
viral
filtrat
process
appli
protein
solut
use
multilay
membran
equival
system
remov
virus
mostli
siev
mechan
introduc
earli
mid
reach
wide
accept
robust
viral
remov
step
essenti
product
apart
albumin
nanofiltr
use
complement
core
viral
inactiv
treatment
provid
enhanc
safeti
nonenvelop
virus
resist
infecti
agent
viru
remov
also
incident
take
place
protein
precipit
chromatographi
filtrat
step
step
contribut
lower
viru
load
protein
product
stream
difficult
monitor
therefor
guarante
standalon
procedur
suffici
safeti
margin
prion
remov
method
variant
creutzfeldtjakob
diseas
vcjd
transmit
red
blood
cell
concentr
date
transmiss
identifi
plasma
plasma
product
biolog
natur
prion
agent
thought
resist
current
viral
inactiv
procedur
use
plasma
fraction
method
known
inactiv
abnorm
misfold
prion
protein
associ
transmiss
spongiform
encephalopathi
prp
tse
oxid
treatment
strong
base
chaotrop
agent
extrem
heat
destroy
plasma
protein
therefor
use
still
modern
process
fraction
product
would
seem
ensur
signific
remov
prp
tse
suggest
experiment
spike
studi
scaledown
experiment
transmiss
spongiform
encephalopathi
tse
spike
model
develop
knowledg
capac
manufactur
process
plasma
protein
remov
prion
grow
rapidli
although
much
uncertainti
remain
unknown
biolog
natur
human
plasma
associ
infecti
agent
sever
process
manufactur
fviii
fibrinogen
von
willebrand
factor
vwf
fix
igg
albumin
product
shown
capabl
remov
prion
consist
reproduc
manner
gener
multistep
fraction
process
thought
contribut
factor
prp
tse
elimin
two
log
remov
spike
prion
occur
standard
protein
purif
step
precipit
ethanol
polyethylen
glycol
peg
anionexchang
chromatographi
depth
filtrat
mechan
remov
may
encompass
adsorpt
mechan
still
fulli
understood
appear
influenc
ph
concentr
precipit
agent
partit
process
may
reflect
prion
aggreg
prion
hydrophob
insolubl
remov
capac
nanofiltr
membran
pore
size
less
nm
extens
investig
prion
remov
like
due
part
molecular
siev
extent
remov
relat
pore
size
filter
presum
aggreg
state
prp
tse
remov
superior
membran
pore
size
nm
compar
nm
natur
origin
spike
agent
use
prp
tse
clearanc
studi
critic
import
variou
spike
differ
size
characterist
brain
homogen
brainderiv
microsom
fraction
infect
anim
usual
use
sourc
prp
tse
spike
materi
reliabl
quantit
detect
method
prp
tse
base
anim
bioassay
requir
mani
anim
time
frame
gener
longer
month
vitro
immunochem
method
western
blot
assay
use
least
first
marker
presenc
prp
tse
associ
infect
detect
proteaseresist
fragment
thu
risk
transmiss
vcjd
human
plasma
product
appear
remot
caution
prevail
sinc
biochem
natur
infecti
agent
human
blood
known
technolog
extract
coagul
factor
proteas
inhibitor
igg
evolv
consider
last
year
lead
develop
product
improv
safeti
puriti
profil
descript
major
manufactur
techniqu
given
factor
viii
sever
gener
fviii
prepar
develop
sinc
provid
safeti
hiv
hcv
hbv
b
improv
puriti
c
enhanc
safeti
hav
current
develop
effort
focu
establish
prion
remov
current
licens
plasmaderiv
fviii
concentr
purifi
cryoprecipit
typic
process
cryoprecipit
subject
combin
aluminium
hydroxid
adsorpt
precipit
precipit
eg
use
glycin
reduc
level
trace
vitamin
k
coagul
factor
may
activ
fviii
downstream
purif
step
load
protein
fibrinogen
purifi
cryoprecipit
extract
usual
undergo
viral
inactiv
typic
sd
pasteur
mani
process
includ
subsequ
chromatographi
anion
exchang
monoclon
antibodi
affin
use
antifviii
antivwf
murin
antibodi
immobil
heparin
affin
remov
protein
contamin
fibrinogen
fibronectin
part
vwf
sd
agent
immunopurifi
fviii
eluat
purifi
chromatographi
remov
murin
igg
ligand
may
leach
prior
formul
steril
filtrat
fviii
product
nanofilt
use
membran
pore
size
even
nm
partial
dissoci
fviii
highmolecularweight
vwf
multim
initi
altern
freezedri
prepar
subject
heat
treatment
inactiv
nonenvelop
virus
like
hav
recoveri
fviii
express
per
liter
plasma
usual
compris
iu
iu
defin
physiolog
activ
present
ml
plasma
factor
lower
fviii
yield
includ
cryoprecipit
ca
loss
chromatograph
purif
ca
viral
heat
inactiv
current
fviii
concentr
specif
activ
iumg
product
formul
human
plasmaderiv
albumin
wherea
other
contain
copurifi
vwf
help
stabil
fviii
puriti
fviii
concentr
convincingli
demonstr
enhanc
immunolog
safeti
longterm
clinic
experi
indic
alleg
reduc
immunosuppress
effect
immunopurifi
prepar
compar
lowerpur
plasmaderiv
prepar
claim
late
probabl
unfound
process
use
part
influenc
residu
vwf
may
impact
immunogen
plasmaderiv
fviii
product
retrospect
studi
previous
untreat
patient
show
sdtreat
nanofilt
ionexchang
purifi
fviii
product
contain
vwf
appear
time
less
like
induc
antifviii
inhibitor
hemophilia
patient
fulllength
recombin
fviii
concentr
von
willebrand
factor
fviii
chromatograph
purif
remov
part
vwf
fviii
product
effect
treat
von
willebrand
diseas
vwd
gener
lowpur
bintermedi
purityq
prepar
prepar
cryoprecipit
precipit
step
coextract
vwf
fviii
ratio
higher
low
puriti
high
protein
content
product
technic
restrict
choic
viral
inactiv
treatment
pasteur
termin
dri
heat
hour
one
highli
purifi
vwf
concentr
larg
devoid
fviii
therefor
specif
vwd
treatment
prepar
cryoprecipit
chromatograph
procedur
integr
fviii
fibrinogen
purif
process
use
anion
exchang
immobil
gelatin
polish
remov
fibronectin
viral
reduct
sd
nanofiltr
termin
dri
heat
hour
fibrinogen
regist
fibrinogen
prepar
avail
treat
fibrinogenemia
hypofibrinogenemia
tradit
prepar
obtain
multipl
precipit
step
plasma
cryoprecipit
use
ethanol
glycin
wherea
modern
product
purifi
chromatographi
viral
reduct
achiev
sd
treatment
often
complement
nanofiltr
termin
dri
heat
treatment
singlestep
pasteur
hour
use
product
fibrin
sealant
fibrin
sealant
fibrin
glue
compris
fibrinogenrich
purifi
thrombin
concentr
mix
compon
strong
adhes
clot
exhibit
hemostat
seal
heal
properti
form
almost
instantan
within
second
offer
multipl
topic
surgic
applic
fibrinogen
prepar
precipit
method
cryoprecipit
cohn
fraction
fraction
may
also
contain
fibronectin
vwf
factor
xiii
fxiii
may
confer
physiolog
function
fibrinogen
fraction
viral
inactiv
sd
pasteur
vaporheat
treatment
andor
nanofiltr
fibrinogen
concentr
typic
gl
may
formul
presenc
antifibrinolyt
agent
prothrombin
complex
prothrombin
complex
concentr
pcc
mixtur
vitamin
kdepend
coagul
factor
fix
factor
ii
factor
x
protein
c
low
specif
activ
iumg
product
contain
also
factor
vii
fvii
usual
level
lower
fix
manufactur
usual
base
method
involv
diethylaminoethyl
deae
sephadex
deae
cellulos
adsorpt
cryopoor
plasma
downstream
ethanol
fraction
also
use
start
materi
anion
exchang
coextract
protein
share
presenc
gammacarboxyglutam
acid
residu
wherea
bulk
plasma
protein
albumin
igg
aat
remain
unbound
fraction
precipit
tricalcium
phosphat
use
one
product
viral
reduct
often
achiev
sd
tnbptween
treatment
complement
nanofiltr
termin
dri
heat
pasteur
vapor
heat
appli
product
viral
inactiv
treatment
sd
requir
one
subsequ
ionexchang
chromatograph
step
remov
virusinactiv
agent
recoveri
rang
iu
fix
per
liter
plasma
singl
fix
highpur
fix
product
develop
late
lead
reduc
risk
thromboembol
compar
pcc
hemophilia
b
patient
fix
isol
chromatograph
purif
pcc
use
anion
exchang
combin
either
immobil
heparin
metal
chelat
affin
monoclon
antibodi
process
yield
fix
concentr
mean
specif
activ
rang
iumg
yield
iul
plasma
factor
vii
three
specif
concentr
rich
fvii
reduc
amount
vitamin
kdepend
clot
factor
current
licens
control
bleed
defici
patient
manufactur
process
includ
ionexchang
chromatographi
aluminium
hydroxid
adsorpt
follow
downstream
procedur
similar
pcc
fix
viral
inactiv
achiev
sd
treatment
vapor
heat
dri
heat
factor
xi
two
factor
xi
fxi
concentr
current
avail
defici
patient
one
low
puriti
purifi
chromatographi
cryopoor
plasma
deae
cellulos
immobil
heparin
freezedri
product
viral
inactiv
dri
heat
product
fxi
captur
adsorpt
filtrat
highli
purifi
cationexchang
chromatographi
product
undergo
dual
viral
reduct
process
sd
nanofiltr
factor
xiii
factor
xiii
transglutaminas
catalyz
final
step
coagul
cascad
crosslink
loos
fibrin
polym
highli
organ
structur
earli
gener
fxiii
concentr
treatment
fxiiidefici
patient
extract
placenta
plasmaderiv
product
subsequ
develop
one
purifi
coldethanol
fraction
cryoprecipit
supernat
purifi
precipit
sodium
citrat
remov
fibrinogen
heat
product
pasteur
sorbitol
solut
ultrafilt
remov
sorbitol
adsorb
bentonit
freezedri
product
obtain
precipit
step
also
pasteur
factor
xiii
also
compon
fibrin
sealant
although
still
subject
discuss
presenc
fxiii
claim
contribut
fibrin
cchain
crosslink
tensil
strength
possibl
improv
hemostat
effect
activ
coagul
factor
human
thrombin
concentr
avail
far
compon
fibrin
sealant
thrombin
prepar
activ
pcc
usual
presenc
calcium
chlorid
follow
viral
inactiv
treatment
sd
purif
cationexchang
chromatographi
viral
remov
nanofiltr
final
thrombin
concentr
usual
iuml
prepar
lower
potenc
avail
slower
speed
clot
format
sealant
prefer
surgic
applic
requir
longer
time
tissu
glu
procedur
largescal
product
purifi
plasmaderiv
fviia
develop
japan
fvii
purifi
anion
exchang
immunoaffin
chromatographi
convert
fviia
autoactiv
anionexchang
resin
incub
presenc
ca
hour
prepar
viral
reduc
nanofiltr
dryheat
intend
treatment
hemophiliac
antibodi
fviii
fix
antithrombin
antithrombin
concentr
first
plasma
product
extract
affin
chromatographi
product
cryopoor
plasma
usual
compris
ion
exchang
chromatographi
remov
pcc
compon
follow
captur
immobil
heparin
viral
inactiv
tradit
achiev
pasteur
presenc
sodium
citrat
combin
sucros
glycin
although
sd
treatment
use
well
heat
treatment
may
partial
denatur
second
adsorpt
step
immobil
heparin
use
remov
alter
molecul
recoveri
ul
plasma
fraction
altern
start
materi
yield
significantli
lower
inhibitor
sever
licens
aat
concentr
includ
unit
state
augment
therapi
indic
treatment
patient
lung
emphysema
secondari
congenit
aat
defici
aat
share
mani
physicochem
properti
particular
molecular
weight
isoelectr
point
albumin
difficult
design
product
method
aat
affect
exist
product
process
albumin
prepar
recov
fraction
iv
purif
wast
fraction
rather
cumbersom
involv
peg
precipit
ionexchang
chromatographi
consider
compromis
recoveri
gl
first
prepar
develop
viral
inactiv
pasteur
dual
viral
reduct
step
use
sd
nanofiltr
also
use
recent
isoelectrofocus
studi
provid
evid
indic
new
anod
aat
variant
present
least
one
fdalicens
product
suggest
alter
isoform
purif
loss
ctermin
posit
charg
lysin
secondari
carboxypeptidas
activ
propos
explan
isoelectrofocus
migrat
shift
circumst
clinic
demand
albumin
decreas
extract
aat
upstream
fraction
supernat
iiiii
appear
logic
trend
offer
possibl
effect
product
scheme
character
recoveri
gl
protein
c
protein
c
concentr
manufactur
europ
japan
one
process
pcc
undergo
cascad
purif
ion
exchang
wherea
immunoaffin
affin
chromatograph
process
combin
ion
exchang
viral
reduct
achiev
sd
treatment
combin
nanofiltr
vaporheat
treatment
inhibitor
inhibitor
concentr
use
treatment
acut
phase
angioedema
primarili
oropharyng
region
gastrointestin
tract
patient
congenit
acquir
defici
product
licens
europ
product
gener
purifi
chromatographi
cryopoor
plasma
extract
pcc
potenti
viral
inactiv
achiev
pasteur
vapor
heat
sd
possibl
combin
nanofiltr
essenti
therapeut
albumin
prepar
prepar
fraction
cryopoor
pccpoor
andor
atpoor
andor
plasma
ethanol
fraction
critic
upstream
process
step
precipit
iiiii
separ
igg
fraction
optim
recoveri
precipit
gener
ethanol
fraction
process
separ
depth
filtrat
albumin
recoveri
gl
puriti
typic
obtain
process
combin
ethanol
fraction
polish
ion
exchang
chromatographi
gener
improv
product
puriti
ca
wherea
one
product
method
albumin
purifi
mostli
anion
exchang
cationexchang
sizeexclus
chromatographi
adjust
concentr
purifi
fraction
typic
achiev
ultrafiltr
standard
viral
inactiv
method
pasteur
accord
pharmacopeia
perform
final
contain
rather
albumin
batch
asept
fill
current
mean
albumin
yield
gl
plasma
polyval
igg
prepar
either
intramuscular
intraven
use
tradit
prepar
fraction
ii
obtain
stepwis
fraction
cryopoor
plasma
use
cold
ethanol
concentr
increasingli
igg
product
extract
upstream
ethanol
precipit
fraction
supernat
iii
precipit
iiiii
optim
recoveri
intermedi
igg
fraction
subject
ionexchang
chromatographi
capryl
acid
peg
precipit
remov
protein
contamin
proteolyt
enzym
andor
aggreg
current
viral
inactiv
procedur
low
ph
incub
pasteur
sd
capryl
acid
treatment
recent
introduc
manufactur
human
igg
product
also
robust
viral
inactiv
process
igg
dedic
viral
remov
nanofiltr
commonli
use
increas
safeti
nonenvelop
virus
especi
situat
core
viral
inactiv
treatment
target
lipidenvelop
virus
igg
recoveri
long
rang
combin
tradit
ethanol
fraction
process
centrifug
depthfiltr
andor
chromatograph
purif
upstream
fraction
improv
mean
recoveri
rang
total
chromatograph
procedur
increasingli
use
product
hyperimmun
igg
product
process
amen
fraction
smaller
plasma
volum
optim
recoveri
manufactur
process
includ
least
dedic
viral
reduct
treatment
protein
compon
fraction
pilotscal
subject
experiment
human
trial
interatrypsin
inhibitor
iti
kunitztyp
serin
proteinas
inhibitor
inhibitori
capac
carri
bikunin
chondroitin
proteoglycan
coval
link
heavi
chain
releas
proteolyt
cleavag
iti
concentr
obtain
fraction
prothrombin
complex
anion
exchang
follow
immobil
heparin
viral
inactiv
sd
iti
reservoir
bikunin
may
involv
control
inflammatori
process
porcin
model
endotoxin
shock
iti
improv
hemodynam
oxygen
coagul
paramet
administr
iti
earli
onset
sepsi
repeat
inject
later
time
point
hour
maintain
cardiovascular
stabil
significantli
reduc
mortal
rat
model
transferrin
major
iron
bind
plasma
protein
may
prevent
cytotox
effect
predisposit
septic
infect
due
accumul
free
nontransferrinbound
iron
normal
iron
use
hamper
andor
apotransferrin
product
decreas
liquid
apotransferrin
concentr
obtain
cohn
fraction
iv
ion
exchang
chromatograph
step
ultrafiltr
viral
safeti
ensur
sd
treatment
nanofiltr
peg
precipit
product
intact
iron
bind
capac
maintain
bacteri
growth
inhibitori
effect
serum
hematolog
stem
cell
transplant
patient
product
prevent
appear
nontransferrinbound
iron
apolipoprotein
ai
princip
protein
compon
plasma
highdens
lipoprotein
prevent
accumul
cholesterolload
macrophag
deposit
arteri
wall
foam
cell
apolipoprotein
ai
inhibit
hepat
lipas
lipoprotein
lipas
vitro
concentr
isol
precipit
cohn
fraction
iii
intraven
inject
men
well
toler
earli
clinic
trial
clinic
observ
consist
combin
inhibit
hepat
lipas
lipoprotein
lipas
activ
possibl
clinic
applic
includ
treatment
hypercholesterolem
patient
atherosclerosi
recombin
lecithin
form
highdens
lipoprotein
complex
could
help
limit
inflamm
endotoxininduc
activ
coagul
fibrinolysi
septic
condit
mannanbind
lectin
mbl
compon
innat
aspecif
immun
system
bind
repetit
structur
mannan
group
surfac
microorgan
activ
complement
system
lead
destruct
larg
varieti
microorgan
rel
frequent
congenit
defici
mbl
associ
recurr
infect
especi
infant
specif
immun
system
yet
matur
mbl
concentr
produc
cohn
fraction
iii
plasmin
major
fibrinolyt
enzym
plasma
encourag
result
new
fibrinolyt
agent
obtain
anim
model
plasmin
appli
directli
clot
cathet
treat
peripher
arteri
occlus
von
willebrand
factor
cleav
proteas
vwfcp
cleav
ultralarg
multim
vwf
enter
blood
stream
directli
biosynthesi
endotheli
cell
develop
purifi
vwfcp
could
use
treat
place
plasma
patient
thrombot
thrombocytopen
purpura
congenit
acquir
defici
vwfcp
activ
protein
c
valu
treatment
sepsi
demonstr
clinic
use
recombin
prepar
therapeut
plasmaderiv
activ
protein
c
product
avail
yet
therapeut
use
although
process
highli
purifi
prepar
cryopoor
plasma
purifi
immunoaffin
anionexchang
chromatograph
step
sd
viral
inactiv
describ
also
research
need
investig
altern
indic
current
avail
product
potenti
clinic
use
aim
benefit
role
inhibitor
attenu
activ
complement
contact
system
includ
septicemia
myocardi
infarct
capillari
leak
syndrom
pancreat
organ
transplant
intraven
use
fxiii
concentr
found
increas
epiderm
growth
factor
transform
growth
factorb
suggest
may
acceler
wound
heal
anastomot
leak
nonheal
fistula
factor
xiii
also
found
osteoinduct
properti
suggest
use
bone
tissu
engin
review
plasma
fraction
also
cover
role
play
nation
intern
regulatori
author
last
year
assur
safeti
largepool
plasma
product
pose
formid
challeng
regulatori
author
fraction
alik
complex
field
encompass
divers
blood
plasma
product
type
manufactur
process
made
difficult
enact
balanc
decis
toward
ensur
product
safeti
guarante
suppli
sinc
agenc
regul
plasma
fraction
industri
develop
comprehens
set
measur
ensur
viral
safeti
plasma
product
multipl
layer
regulatori
oversight
plasma
industri
establish
ensur
overlap
safeguard
risk
transmiss
bloodborn
infecti
agent
sever
regul
guidanc
posit
statement
issu
agenc
like
us
fda
european
medicin
evalu
agenc
updat
need
cover
import
safeti
aspect
requir
stage
manufactur
chain
activ
blood
establish
prepar
plasma
fraction
extend
manufactur
distribut
plasma
product
regulatori
oversight
includ
epidemiolog
surveil
donor
popul
donor
deferr
polici
screen
practic
mandatori
donat
test
test
manufactur
plasma
pool
valid
viral
reduct
procedur
product
step
well
assess
product
qualiti
safeti
efficaci
market
author
relev
inform
plasma
collect
assembl
europ
plasma
master
file
allow
establish
key
level
inform
regard
qualiti
safeti
plasma
raw
materi
post
market
report
advers
reaction
associ
plasma
product
transmit
nra
could
prompt
emerg
respons
procedur
product
recal
harmon
requir
manufactur
suppli
plasma
product
unit
state
europ
japan
take
place
auspic
intern
confer
harmonis
much
work
remain
done
measur
nonetheless
provid
framework
modern
plasma
product
exhibit
high
level
qualiti
safeti
efficaci
howev
rigid
regulatori
system
impedi
signific
technolog
evolut
plasma
fraction
process
process
chang
current
associ
major
regulatori
work
cohn
plasma
fraction
method
initi
design
obtain
albumin
year
develop
rather
success
wellestablish
industri
procedur
isol
wide
rang
clinic
use
product
today
differ
protein
product
one
consid
varieti
hyperimmun
igg
prepar
extract
largescal
fraction
human
plasma
sound
largescal
adapt
technolog
one
hand
rigid
current
regulatori
framework
explain
technolog
remain
main
core
method
use
industri
scale
although
impli
suboptim
yield
protein
apart
albumin
technolog
increas
complex
year
greatest
progress
purif
without
doubt
associ
use
chromatograph
method
made
possibl
develop
new
protein
therapeut
impress
improv
product
puriti
qualiti
fraction
scheme
also
chang
dramat
introduct
inprocess
viral
reduct
treatment
requir
addit
downstream
techniqu
chromatographi
ultrafiltr
chang
protein
driver
promin
clinic
role
play
igg
requir
increas
protein
recoveri
optim
fraction
process
may
crystal
incent
fraction
abandon
rel
technic
conservat
introduc
signific
technolog
chang
process
technolog
product
igg
precipit
iiiii
alreadi
implement
manufactur
possibl
aat
supernat
iiiii
sign
gradual
evolut
direct
total
chromatograph
process
much
gain
last
year
understand
key
paramet
build
plasma
product
qualiti
safeti
efficaci
one
hope
regulatori
path
particular
regard
clinic
studi
licens
known
protein
therapeut
prepar
improv
effici
technolog
simplifi
would
turn
contribut
improv
suppli
plasma
fraction
industri
far
target
mostli
protein
obviou
candid
replac
therapi
also
hope
invest
develop
new
product
plasma
remain
uniqu
sourc
potenti
therapeut
protein
proactiv
research
develop
work
encourag
isol
evalu
new
therapi
among
well
character
plasma
protein
still
unknown
function
final
one
forget
plasma
protein
therapi
expens
larg
inaccess
develop
world
new
market
driver
rich
countri
like
diminish
econom
interest
manufactur
fviii
remain
major
protein
therapi
need
develop
world
belief
decreas
use
plasmaderiv
fviii
fix
develop
economi
hemophiliac
switch
recombin
therapi
would
increas
suppli
product
develop
countri
may
econom
viabl
rather
switch
recombin
product
rich
countri
make
poor
countri
unabl
afford
increas
cost
product
longer
subsid
premium
price
paid
rich
countri
therefor
remain
import
develop
afford
viral
inactiv
process
technolog
gradual
allow
develop
countri
make
use
local
plasma
resourc
safe
manner
